Drug Parkinson'S Disease

Inbrija

Payments companies reported to CMS as associated with Inbrija. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.2Massociated payments (2023-2025)
3,982clinicians with associated payments
2companies reporting

By year

2023 $499K
2024 $241K
2025 $484K

Payments reported as associated with Inbrija, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Neurology (Psychiatry & Neurology) $1.0M
Family $33K
Physician Assistant $29K
Nurse Practitioner $25K
Psychiatry $21K
Gastroenterology (Internal Medicine) $13K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Inbrija

These are the largest totals companies reported as associated with Inbrija. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Stuart Isaacson Boca Raton, FL Neurology (Psychiatry & Neurology) $94,335.57
Maria Ospina Phoenix, AZ Neurology (Psychiatry & Neurology) $66,969.06
Ramsey Falconer Alexandria, VA Neurology (Psychiatry & Neurology) $63,885.15
Aasef Shaikh Cleveland, OH Neurology (Psychiatry & Neurology) $55,447.02
Daniel Kremens Philadelphia, PA Neurology (Psychiatry & Neurology) $54,887.72
Ramon Rodriguez Cruz Orlando, FL Neurology (Psychiatry & Neurology) $51,518.76
Aashoo Mentreddi York, ME Neurology (Psychiatry & Neurology) $44,950.50
Cherian Karunapuzha Oklahoma City, OK Neurology (Psychiatry & Neurology) $42,635.06
Laxman Bahroo Washington, DC Neurology (Psychiatry & Neurology) $40,609.36
Indu Subramanian Los Angeles, CA Neurology (Psychiatry & Neurology) $38,973.34

Prescribed Inbrija?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.